Please use this identifier to cite or link to this item: https://doi.org/10.3978/j.issn.1000-9604.2013.11.12
Title: Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation
Authors: Li, J.
Pan, J.
Zhu, X.
Su, Y.
Bao, L.
Qiu, S.
Zou, C.
Cai, Y.
Wu, J.
Tham, I.W.K. 
Keywords: Pancreatic carcinoma
Radiosensitization
Recombinant adenovirus-p53 (rad-p53)
Transfection
Issue Date: 2013
Citation: Li, J., Pan, J., Zhu, X., Su, Y., Bao, L., Qiu, S., Zou, C., Cai, Y., Wu, J., Tham, I.W.K. (2013). Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation. Chinese Journal of Cancer Research 25 (6) : 715-721. ScholarBank@NUS Repository. https://doi.org/10.3978/j.issn.1000-9604.2013.11.12
Abstract: Objective: In this study, we examine the effects of recombinant adenovirus-p53 (rAd-p53) on the pancreatic carcinoma cell line SW1990. Specifically, we determine if expression of rAd-p53 sensitizes these cells to radiation. Methods: Following transfection of SW1990 cells with rAd-p53, we measured expression of P53, P21 and Bax by immunocytochemistry. Both transfected and control cell lines were irradiated with a range of doses, and the survival fractions (SF) were calculated. Dose survival curves were constructed and modeled for comparison. Results: Transfection of SW1990 cells with rAd-p53 resulted in increased expression of P53, P21 and Bax in a time-dependent manner. At 96 h after transfection, 89.92% of cells expressed P53, 56.8% expressed P21, and 76.50% expressed Bax. The SF following radiation was lower in the rAd-p53 transfected cells compared to the control cells, suggesting that rAd-p53 sensitizes SW1990 cells to radiation (D0 for the experimental and control groups was 2.199 and 2.462, respectively). Conclusions: Use of the adenoviral vector is an effective means of transfecting SW1990 cells with wild-type P53, and this sensitizes the cell line to irradiation. This work suggests that combining rAd-p53 with radiation therapy in pancreatic cancer may be therapeutically beneficial. © Chinese Journal of Cancer Research. All rights reserved.
Source Title: Chinese Journal of Cancer Research
URI: http://scholarbank.nus.edu.sg/handle/10635/125445
ISSN: 19930631
DOI: 10.3978/j.issn.1000-9604.2013.11.12
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.